Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells

Table 1

The baseline data of 13 pancreatic cancer patients.

Code number	Sex/age (years)	Diagnosis	Chemotherapy	CIK cycles	Treatment response	OS (months)	Adverse events
1	F/61	Hepatic metastasis of pancreatic adenocarcinoma after operation	S-1	2	PD	3.07	II° Diarrhea
2	M/58	Hepatic metastasis of pancreatic cancer	Gemcitabine	11	PD	4.00	III° Thrombocytopenia
3	F/76	Hepatic metastasis of pancreatic cancer	No	6	SD	6.20	Mild fever
4	M/49	Hepatic metastasis of pancreatic cancer	S-1	2	SD	7.77	/
5	F/49	Liver and lymph nodes metastasis of pancreatic adenocarcinoma after operation	S-1	12	SD	7.80	Fatigue and anorexia
6	M/70	Lung metastasis of pancreatic head cancer	Gemcitabine	6	SD	9.90	III° Diarrhea and II° bone marrow suppression
7	M/71	Liver and adrenal metastasis of pancreatic cancer	S-1	4	SD	10.57	/
8	M/58	Abdominal metastasis of pancreatic adenocarcinoma	Gemcitabine	9	SD	11.2	II° Bone marrow suppression
9	F/79	Bone and liver metastasis of pancreatic adenocarcinoma after operation	No	4	SD	17.07	/
10	M/72	Hepatic metastasis of pancreatic adenocarcinoma	S-1	20	PR	17.30	/
11	M/52	Gastric and duodenal metastasis of pancreatic head adenocarcinoma	No	12	SD	19.07	/
12	F/74	Lung metastasis of pancreatic head adenocarcinoma	S-1	25	PR	19.40	Fatigue and anorexia
13	F/77	Peritoneal metastasis of pancreatic adenocarcinoma after operation	No	40	CR	36.53	/

M, male; F, female.
Patient alive.
CR: complete remission, PR: partial remission, SD: stable disease, and PD: progressive disease.